TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11872282
Drug: Once-daily thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily thoracic radiation
Study: 11872282
Drug: Twice-daily thoracic
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily thoracic radiation
Study: 10442374
Drug: UFT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT plus cisplatin with concurrent radiotherapy
Study: 2185625
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g glucose
Study: 2185625
Drug: 0.9 g
Normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g uncooked cornstarch
Study: 2185625
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g glucose followed 20 min later by 1.75 g fructose
Study: 2185625
Drug: 0.9 g
Normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g uncooked cornstarch followed 20 min later by 1.75 g fructose
Study: 2185625
Drug: Water followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water followed 20 min later by 1.75 g fructose
Study: 2185625
Drug: Urinary chromium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary chromium excretion
Study: 25921600
Drug: Curcumin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (150 mg, theracurmin)
Study: 14750002
Drug: Sweetened matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweetened matrix formulation of OTFC (200 microg fentanyl)
Study: 14750002
Drug: Compressed powder
Normalized name: Ulva compressa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compressed powder formulation of OTFC (200 microg fentanyl)
Study: 9926788
Drug: Modified laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified laparoscopic intraperitoneal onlay mesh herniorrhaphy (IPOM) using a meshed expanded polytetrafluorethylene (ePTFE) soft tissue patch
Study: 16756416
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (TN) 42 mg
Study: 8143465
Drug: Aerosolized ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aerosolized ribavirin (20 mg/mL) for 18 hrs/day for 5 days
Study: 3065506
Drug: Nisoldipine, 10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine, 10-20 mg daily
Study: 31606437
Drug: Sofosbuvir plus
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir plus velpatasvir treatment
Study: 27099485
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg once a day for 3 days, then 250 mg once every 2 days for 3 months)
Study: 23415640
Drug: Orofacial manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orofacial manual therapy in addition to cervical manual therapy
Study: 23415640
Drug: Cervical manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical manual therapy (usual care)
Study: 2548759
Drug: Intracoronary injections
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injections of salbutamol
Study: 2548759
Drug: Intracoronary injections
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injections of salbutamol after practolol (beta 1-selective blockade)
Study: 2548759
Drug: Intracoronary injections
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injections of salbutamol after propranolol (beta 1- and beta 2-blockade)
Study: 2103760
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg t.d.s.)
Study: 326491
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg q.d.s.)
Study: 31090563
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral feeding after MIE
Study: 25723614
Drug: Standard-dose adalimumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose adalimumab (9.48 +/- 5.61 g/mL)
Study: 25723614
Drug: Low-dose adalimumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adalimumab (3.51 +/- 2.21 g/mL)
Study: 25723614
Drug: Adalimumab dose
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab dose escalation from every other week to weekly
Study: 23262179
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone (0.15mg/kg)
Study: 23262179
Drug: High-dose hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hydrocortisone (0.45mg/kg)
Study: 19543144
Drug: Lactobacillus crispatus
Normalized name: LACTOBACILLUS CRISPATUS
DrugBank: Lactobacillus crispatus strain CTV-05 (DB19093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus crispatus CTV-05 (LACTIN-V) administered by vaginal applicator at doses of 5 x 10, 1 x 10, and 2 x 10 cfu/dose for 5 consecutive days
Study: 19543144
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by vaginal applicator
Study: 9815725
Drug: neoadjuvant chemoendocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemoendocrine therapy (four 3‐weekly cycles of chemotherapy with mitozantrone, methotrexate (+/‐ mitomycin C), and tamoxifen)
Study: 9815725
Drug: neoadjuvant chemoendocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemoendocrine therapy
Study: 30238870
Drug: 10-ml/kg fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-ml/kg fluid bolus
Study: 30238870
Drug: 20-ml/kg fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-ml/kg fluid bolus
Study: 24851943
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA) with continuous administration of 0.25% bupivacaine
Study: 24851943
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia alone with intravenous analgesia (fentanyl: intubation 2 µg/kg; maintenance 0.1‐0.3 mg)
Study: 12593597
Drug: Naproxen (275
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (275 mg)
Study: 8450107
Drug: Enhanced Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Behavioral Marital Therapy (EBMT)
Study: 25008579
Drug: Soy-protein diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-protein diet (30 g/d soy protein)
Study: 15709987
Drug: CDP571 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 (20 mg/kg at week 0 and 10 mg/kg at week 8)
Study: 27029918
Drug: Iron-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-enriched yeast (2.5 mg 58Fe)
Study: 27029918
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (2.5 mg 57Fe)
Study: 27029918
Drug: Iron-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-enriched yeast (2.5 mg 58Fe) with bread and butter
Study: 27029918
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (2.5 mg 57Fe) with bread and butter
Study: 25836918
Drug: Hydroxytyrosol 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxytyrosol 5 mg/d
Study: 25836918
Drug: Hydroxytyrosol 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxytyrosol 25 mg/d
Study: 25836918
Drug: Hydroxytyrosol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxytyrosol (both doses)
Study: 24050512
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d) (EBMT)
Study: 24050512
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.) (MEA)
Study: 14697022
Drug: Control (air
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (air treatment)
Study: 11360072
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (2.5 ml of 0.5% bupivicaine)
Study: 11360072
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia (15 ml of 0.5% bupivicaine)
Study: 9125675
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of acetazolamide with diuretic therapy
Study: 9125675
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with hydrochlorothiazide or furosemide
Study: 8150549
Drug: Cefpirome 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 1.0 g
Study: 2878632
Drug: Beta 2-agonist
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2-agonist terbutaline (5 mg)
Study: 2878632
Drug: Beta 1
Normalized name: Beta 1 Kit
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta 1 + 2-agonist orciprenaline (10 mg)
Study: 2878632
Drug: Beta 1-antagonist
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 1-antagonist acebutolol (200 mg)
Study: 2878632
Drug: Beta 1-antagonist
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 1-antagonist metoprolol (50 mg)
Study: 2878632
Drug: Beta 1
Normalized name: Beta 1 Kit
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta 1 + 2-antagonist propranolol (5 mg)
Study: 2878632
Drug: Beta 1
Normalized name: Beta 1 Kit
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta 1 + 2-antagonist with ISA pindolol (5 mg)
Study: 2878632
Drug: Beta 1-antagonists
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 1-antagonists (acebutolol and metoprolol)
Study: 27035842
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion 0.5 μg/kg/h throughout the surgery after a loading dose of 1 μg/kg over 10 minutes, continued at 0.2 μg/kg/h for 24 hours postoperatively
Study: 26154345
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training + protein (whey 17 g + colostrum 3 g + leucine 2 g)
Study: 8062311
Drug: Uniphyl (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl (once-daily theophylline) in No Time Lapse (NTL) group
Study: 8062311
Drug: Uniphyl (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl (once-daily theophylline) in Time Lapse (TL) group
Study: 2661612
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 5, 10, 15, 20 mg
Study: 29753370
Drug: High-dose irbesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose irbesartan combined with spironolactone (group D)
Study: 29753370
Drug: Low-dose irbesartan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose irbesartan combined with spironolactone (group C)
Study: 23536690
Drug: MF59-adjuvanted tetravalent
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted tetravalent influenza vaccine
Study: 23536690
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of tetravalent influenza vaccine
Study: 23536690
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of MF59-adjuvanted A/H5N1 vaccine
Study: 22235686
Drug: Qilin Pills,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilin Pills, 6 g tid for 12 weeks
Study: 22235686
Drug: Wuziyanzong Pills,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuziyanzong Pills, 6 g bid for 12 weeks
Study: 22235686
Drug: Qilin Pills
Normalized name: Qilib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilin Pills
Study: 22235686
Drug: Wuziyanzong Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuziyanzong Pills
Study: 17181378
Drug: Subcutaneous PTH(1-84)
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous PTH(1-84) 100 microg/day
Study: 17181378
Drug: Subcutaneous PTH(1-84)
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous PTH(1-84) 100 microg/day followed by alendronate 10 mg/day
Study: 17181378
Drug: PTH(1-84) in
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH(1-84) in combination with alendronate
Study: 11732460
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration (DTP‐HBV‐Hib)
Study: 11732460
Drug: Separate administrations
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administrations of DTP‐HBV and Hib vaccines
Study: 3134739
Drug: Magnyl (plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnyl (plain acetylsalicylic acid) 75 mg daily for 2 weeks
Study: 3134739
Drug: Globentyl (micro-encapsulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Globentyl (micro-encapsulated acetylsalicylic acid) 75 mg daily for 2 weeks
Study: 27148676
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg by mouth once daily, with a possible increase to 200 mg depending on response)
Study: 23277434
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between EVLW-T and EVLW-G
Study: 9915315
Drug: Milrinone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (30 microg/kg bolus administered progressively in 10 min, followed by a continuous infusion of 0.5 microg x kg(‐1) x min(‐1))
Study: 7675954
Drug: 8.33 mg
Normalized name: ombitasvir 8.33 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.33 mg phenylpropanolamine gum
Study: 1665178
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg and Hydrochlorothiazide 12.5 mg once daily (L/HCTZ)
Study: 1665178
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg and Hydrochlorothiazide 25 mg once daily (C/HCTZ)
Study: 7235321
Drug: Metaproterenol metered
Normalized name: metaproterenol Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol metered dose aerosol (1.5 mg)
Study: 25056444
Drug: Placebo expectation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo expectation group (told the cream would reduce pain)
Study: 25056444
Drug: No-expectation group
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-expectation group (told the cream was a hand cleanser)
Study: 23436265
Drug: etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etravirine 200 mg bid for 8 days
Study: 23436265
Drug: lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir 400/100 mg bid for 16 days with etravirine 200 mg bid on days 9-16
Study: 21045816
Drug: EST followed
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EST followed by mechanical lithotripsy (ML)
Study: 9084513
Drug: Manually controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually controlled infusion of propofol (10‐12 mg/kg/h) and alfentanil (25 micrograms/kg/h) for 2 min, followed by atracurium (5 mg) and propofol (1‐1.5 mg/kg) as a bolus induction dose over 20 s.
Study: 9084513
Drug: Thiamylal (4‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal (4‐5 mg/kg) and fentanyl (2 micrograms/kg), atracurium (5 mg) and succinylcholine (1.5 mg/kg).
Study: 9084513
Drug: Thiamylal (4‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal (4‐5 mg/kg) with additional sublingual nifedipine (1/2 capsule) 10 min prior to induction.
Study: 1879184
Drug: Intramuscular imipenem/cilastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular imipenem/cilastatin (500 or 750 mg every 12 hours)
Study: 1879184
Drug: Intramuscular imipenem/cilastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular imipenem/cilastatin
Study: 1879184
Drug: Intramuscular imipenem/cilastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular imipenem/cilastatin (500 mg)
Study: 24300843
Drug: Half-dose sinogram-affirmed
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose sinogram-affirmed iterative reconstruction (HD-SAFIRE(2))
Study: 24300843
Drug: Full-dose filtered
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose filtered back projection images (FD-FBP)
Study: 19139424
Drug: Cisplatin-based concurrent
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based concurrent chemoradiotherapy
Study: 19139424
Drug: Mitomycin-based therapy
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-based therapy
Study: 15528874
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with losartan and trandolapril
Study: 2694142
Drug: Chlortenoxicam 4
Normalized name: Chlortenoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlortenoxicam 4 mg
Study: 411434
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin infusion at the rate of 6 units per hour
Study: 411434
Drug: High-dose, intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose, intermittent subcutaneously administered insulin
Study: 26474517
Drug: Cediranib 20
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 20 mg orally once daily until disease progression
Study: 23815798
Drug: Prothrombin complex
Normalized name: prothrombin complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothrombin complex concentrate administration prior to surgery
Study: 23815798
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration prior to surgery
Study: 15285023
Drug: DA-9601 180
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-9601 180 mg
Study: 15285023
Drug: DA-9601 360
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-9601 360 mg
Study: 15285023
Drug: Cetraxate 600
Normalized name: Cetraxal
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetraxate 600 mg
Study: 9269642
Drug: RenaGel 1
Normalized name: RenaGel
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RenaGel 1 g
Study: 9269642
Drug: RenaGel 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RenaGel 2.5 g
Study: 9269642
Drug: RenaGel 5
Normalized name: RenaGel
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RenaGel 5 g
Study: 1586329
Drug: Intravenous Syntocinon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Syntocinon
Study: 3308584
Drug: Exogenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous insulin
Study: 18373318
Drug: MCP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCP treatment for 30 minutes during eight days
Study: 18373318
Drug: No MCP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No MCP treatment
Study: 8655293
Drug: Pentoxifylline at
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline at a dose of 800 mg thrice daily
Study: 435053
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no albumin therapy)
Study: 6312460
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefotiam twice daily for 10 days
Study: 6312460
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cephalothin 4-times daily for 10 days
Study: 30778742
Drug: Receiving chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving chemotherapy
Study: 26475499
Drug: 0.12 %
Normalized name: Oris 0.12 % Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 % CHX + 0.05 % CPC (Perio-Aid® Treatment alcohol-free)
Study: 26475499
Drug: 0.03 %
Normalized name: menthol 0.03 % Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 % CHX + 0.05 % CPC new test formulation
Study: 11872656
Drug: Increased plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased plasma amino acids (approximately 4.6 mmol/l)
Study: 523673
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) administered via tablets, gel, and pessary bases
Study: 27681813
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections of hyaluronic acid 1.6% (group A)
Study: 27681813
Drug: Syalox 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syalox 300 Plus® (hyaluronic acid 300 mg + Boswellia serrata extract 100 mg) for 20 days followed by Syalox 150® (hyaluronic acid 150 mg) for another 20 days (group B)
Study: 19438847
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (250-1000 mg/bid i.v.) plus hypertonic saline solutions (150 mL H(2)O with NaCl 1.4-4.6%)
Study: 19438847
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide plus hypertonic saline solutions
Study: 19438847
Drug: Repeated paracentesis
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated paracentesis and standard diuretic schedule
Study: 8346832
Drug: Nitroprusside and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside and diltiazem (bolus of 80 micrograms/kg with two consecutive infusions of 4.5 micrograms.kg‐1.min‐1 during the first 30 min and then 1.3 micrograms.kg‐1.min‐1)